NEWS: Intercell vaccine patch fails Phase II clinical trial
Intercell's investigational vaccine enhancement patch system for avian H5N1 influenza has failed a Phase II study. The company is working under a contract with Human and Health services (HHS) to develop a dose-sparing approach with potential for a single dose immunization combining a H5N1 vaccine with Intercell's LT adjuvant patch.